gbola amusa md cfa head hc research
sale trade et
viral news genet medicin drop condit collab
highlight week march march rubiu therapeut unrat announc compani
depriorit red cell-bas therapi phenylketonuria pku factor contribut decis includ
delay due manufactur high product cost chronic high-dos therapi continu momentum
compani oncolog pipelin recal compani announc januari dose patient
phase ib trial therapi well toler result uninterpret possibl due part
low dose cell administ sensit assay use trial discontinu rocket
buy forti seven unrat announc collabor focus antibody-bas condit
regimen ex vivo lentivir vector hematopoiet stem cell lvv -base gene therapi gt fanconi
anemia fa current clinic studi incorpor condit regimen surviv advantag
confer gene correct enabl engraft expans modifi cell time expect incorpor
condit regimen could acceler correct cell engraft arcturu therapeut buy announc
file ind fda advanc mrna-bas therapeut first-in-man studi ornithin
transcarbamylas over-the-counter defici detail whether would first test healthi volunt
provid howev us safeti data patient first drug base new platform technolog usual creat
valu compani also join effort develop vaccin use starr platform design
self-repl rna lnp deliveri system buy chardan top pick announc
result provid updat catalyst compani continu expect start pivot trial
base gt b-vec deb announc interim phase i/ii data gt defici arci
see best-cas approv b-vec model base case assum launch given
rmat design possibl earli file addit ind filingson aesthet skin indic one
rare skin indicationar plan given uniqu first-mov statu krystal platform
continu believ potenti launch b-vec would signal launch follow
look forward march march follow compani report financi result hookipa pharma
unrat march et vbl buy march et
weekli price move chardan genet medicin vivo gene therapi ex vivo gene therapi
upcom chardan genet medicin event contact chardan rsvp
may tent chardan host biotech network night asgct annual meet boston
gene express convers glial cell neuron treat huntington diseas
pennsylvania state univers publish preclin result potenti disease-modifi
approach huntington diseas hd recal hd thought caus expans trinucleotid
repeat htt gene present often uncontrol movement deterior cognit among
physiolog chang report preferenti degener medium spini gaba neuron msn striatum
author studi report use aav-bas gene therapi convert striatal astrocyt msn mous
model hd brief express two transcript factor convert astrocyt gabaerg
neuron assess express neuron marker neun sever gabaerg marker includ
pleas refer import disclosur inform regul analyst certif found page report
gaba function analysi reveal signific differ na current convert non-convert
neuron mice signific differ spontan excitatori inhibitori postsynapt current
convert non-convert neuron phenotyp deficit report correct treat mice extent
stride-length model motor function improv treat mice rel control-tr
though earli stage note innov aspect approach consid cell engin field like benefit
advanc synthet biolog allow fine-tun approach one key limit studi context
hd persist expans convert astrocyt consequ favor approach includ
crispr gene regul target transcript knockdown directli affect toxic transgen express
sangamo unrat collabor takeda unrat develop zinc finger protein zfp -base
vivo gene regul strategi select repress express mutant htt allel uniqur buy chardan
top pick develop gt encod microrna target huntingtin gene
design specif inhibit mutant protein product see march research compani expect
dose patient end
buy pt b-vec track launch march amusa
buy chardan top pick announc result provid updat catalyst
understand pivot phase trial hsv-base gt b-vec deb still design studi mean
bla file still possibl although think like given rmat design
b-vec deb best-cas scenario fda approv ahead long-held
increas pt roll forward dcf mean quarter neg forward
remov result estim materi chang
buy ftsv collab condit could long-term ex vivo march livshit
rocket pharmaceut forti seven unrat announc collabor focus antibody-bas
condit regimen fanconi anemia fa
would expect incorpor condit regimen acceler correct cell engraft perhap
increas final proport engraft cell plateau believ antibody-bas regimen could therefor
present rout boost efficaci without compromis safeti potenti could improv toler
incorpor rocket ex vivo program current use standard condit regimen
deal us signal continu interest develop non-genotox condit regimen ex vivo gene
therapi forti seven alreadi collabor unrat bluebird bio test regimen bluebird ex
vivo lentivir program unrat develop antibody-bas condit strategi
unrat announc collabor unrat condit
regimen therapi vertex develop collabor buy-rat crispr
arct buy co achiev mileston file first ind march naka
arcturu file ind fda advanc mrna-bas therapeut first-in-man
studi ornithin transcarbamylas over-the-counter defici base statement manag unclear us
studi includ test cohort normal healthi volunt opinion bypass test normal
healthi volunt first-in-man studi would unwis done sake expedi reduc expens
amass safeti databas patient first drug base new platform technolog usual creat valu
arcturu also join effort develop vaccin compani believ potenti
advantag vaccin would lower volum requir effect dose would cheaper
manufactur
buy see updat key catalyst march livshit
report result provid guidanc aavhsc base gene
therapi phenylketonuria pku data updat anticip upon select dose expans
portion phase i/ii phenix trial
note februari initi base initi safety/act data phenix patient report
decemb coupl preclin dose-respons simul see reason likelihood program
reach primari efficaci endpoint random portion mol/l plasma phenylalanin dose level
page
dose level reach mol/l could increas confid program might expect
delay homolog need amend studi protocol enabl higher dose
genet medicin news march march
unrat receiv orphan drug design fda cystinosi march
unrat announc financi result provid busi updat march
kuur privat announc develop off-the-shelf car-nkt cell therapi march
kuur formerli cell medica announc new busi partnership baylor colleg medicin
develop car-nkt cell therapi platform anti-canc therapi compani focu phase studi
malign neuroblastoma preclin work hepatocellular carcinoma
unlik regular cell nkt cell mediat graft-versus-host diseas gvhd make suitabl use
allogen set like allogen therapi engin gene edit nkt cell product
could therefor avail dose off-the-shelf less costli manufactur compar patient-specif
cll unrat announc patent method prepar allogen t-cell crispr march
freelin privat announc odd ec aav-bas gt fabri diseas march
phio unrat announc collabor option agreement unrat medigen march
unrat appoint dr lisa johnson-pratt senior vice presid new product strategi march
unrat appoint geno germano board director march
unrat announc financi result provid corpor updat march
hannov medic school publish hcmv gb cell cord blood-deriv cell march
trvx unrat announc financi result provid busi updat march
tng fp unrat announc result provid corpor updat march
excis privat report data crispr-bas inactiv viral dna nhp march
excis biotherapeut announc data ind-en studi support use therapi
hiv elimin vector deliv iv administr indian rhesu macaqu
well toler demonstr broad biodistribut cell type known viral reservoir
pcr analysi siv genom blood sampl show evid viral genom excis includ presenc
truncat ltr-gag fragment
data us show potenti edit latent reserv viru howev extent edit remain unclear
note unrat publish ex vivo zinc-fing nuclease-bas gene therapi approach
treat hiv base excis viral entri co-factor studi met primari safeti endpoint
unrat announc result provid oper updat march
curevac privat announc ingmar hoerr succe daniel menichella ceo march
horama privat announc appoint rodolph clerval chief busi offic march
unrat announc result provid busi updat march
rubiu announc result provid updat red cell-bas therapi
program pku compani depriorit program cite delay due manufactur high product
cost chronic high-dos therapi continu momentum compani oncolog pipelin
compani announc januari dose patient phase ib trial
therapi well toler result uninterpret possibl due part low dose cell administ
sensit assay use trial discontinu
addit manufactur logist challeng program face competit sever
compani genet medicin space see competit pku landscap februari research
among believ aav-bas gt approach buy
unrat deliv optim transgen compar approach buy rate
simpler manufactur
selb unrat announc result provid updat oper march
page
ly fp unrat announc million capit increas sale new ordinari share march
exuma biotech privat announc mm seri tx solid liquid tumor march
unrat announc result provid corpor updat march
unrat announc mm grant deliveri devic dna vaccin march
arcellx privat announc receipt odd cart-ddbcma multipl myeloma march
buy announc result provid corpor updat march
report net loss mm januari solid announc reduct workforc
approxim one third implement part strateg plan design priorit develop
solid announc biomark data patient dose vg/kg dose cohort ignit dmd
compani phase i/ii clinic trial
rgl unrat announc result provid corpor updat march
sight fp buy announc result provid busi updat march
gensight biolog announc fda meet expect discuss manufactur qualiti aspect
agenc pend result phase reflect trial expect necessari submiss
applic market author unit state
gensight plan pre-submiss meet ema earli expect submit applic
eukari privat appoint guillaum prunier special advisor presid march
buy announc result provid updat oper march
meiragtx chardan top pick report earn mm significantli beat ccme mm
due benefit janssen entiti unrat johnson johnson collabor
march ema grant prioriti medicin prime advanc therapi medicin product atmp
design aav-bas gt aav-rpgr prime design grant base clinic data on-going
phase i/ii trial xlrp
blcm unrat announc financi result provid corpor updat march
askbio privat announc appoint tim kelli presid manufactur march
buy announc financi result provid busi updat march
report earn mm line ccme mm
compani complet patient dose cohort optic phase clinic trial gt
wet patient screen cohort cohort patient receiv prophylact topic
steroid eye drop total week instead prophylact oral steroid day use cohort
unrat announc financi result provid oper updat march
unrat announc financi result provid corpor updat march
uc boulder publish small molecul regul bacteri genom edit march
ucla publish oncolyt vaccinia viru express inhibitor gm-csf march
osaka univers publish nanovesicl transient deliveri genom edit therapi march
compani mention report
page
page
select catalyst genet medicin coverag
lumasiran report top-line result illuminate-a trial primari hyperoxaluria type
nedosiran report multi-dos data phyox open-label trial primari hyperoxaluria
report preliminari result phase ia/iib trial healthi volunt hbv subject
complet phase optic cohort dose begin cohort enrol wet
lunar-otc file ind ornithin transcarbamylas over-the-counter defici
dose patient clear cell renal cell carcinoma
zolgensma anticip approv eu sma
pre-submiss meet ema
initi investigator-initi phase ii studi recurr glioblastoma
report interim biomark analysi oval phase studi ovarian cancer
xlrp end-of-phas ii meet fda xlrp
nedosiran complet enrol trial primari hyperoxaluria
report addit process data fanconi anemia
submit ind diabet retinopathi
aro-enac file cta cystic fibrosi
present initi clinic data cardiovascular diseas
initi long-term follow-up initi patient phase i/ii studi batten diseas
b-vec initi pivot phase trial deb
report top-line interim result phase i/ii poc trial arci
initi phase i/ii trial methylmalon acidemia mma
nomin develop candid
initi phase ib studi liver kidney transplant recipi cscc
select lead product candid
complet assess cohort phase i/iia trial wet
suprachoroid initi phase ii trial wet use microinjector
suprachoroid submit ind phase ii trial dr use microinjector
report data secondari endpoint expand cohort phase i/ii hofh
zolgensma anticip approv japan sma
complet enrol phase i/ii pioneer trial retin pigmentosa
givosiran report addit result envison trial acut hepat porphyria
report phase data hypertriglyceridemia
report phase data dyslipidemia
aro-aat report biopsi data phase ii open label studi antitrypsin defici
report updat data phase i/ii trial pku announc expans cohort dose
submit ind attr
report result phase ii nivolumab combin studi skin cancer cohort
provid interim data cohort phase i/ii trial mp ii
provid program updat preclin develop diseas
figur dicerna krystal expect import data read-out
page
select catalyst genet medicin coverag
report interim analysi phase ii trial cmv
report top-line result phase reflect trial lhon
report top-line result realiti observ natur histori studi lhon
submit ema lhon
report top-line result cohort phase i/ii pioneer trial retin pigmentosa
report multipl dose data chronic hepat infect
initi phase i/ii trial diabet retinopathi
present data phase optic studi wet
report data phase i/ii trial
xlrp report interim analysi group mo data group pi/ii trial xlrp
dose patient phase i/ii trial antitrypsin defici
report initi data phase i/ii studi batten diseas
b-vec initi clinic studi eu deb
report preliminari data phase i/ii trial methylmalon acidemia mma
initi dose patient clinic studi attr
report initi phase data danon diseas
report updat data phase i/ii trial lad-i
report preliminari phase data pyruv kinas defici
report preliminari phase ii data fanconi anemia
submit ind diseas
initi pivot trial subretin deliveri wet
suprachoroid initi phase ii trial dr use microinjector
suprachoroid interim data cohort wet w/ microinjector
submit bla fda lhon
program file ind oncology/inflammatori indic
lumasiran potenti fda/ema approv primari hyperoxaluria type
etranadez report top-line data pt pivot phase hope-b studi hem
zolgensma anticip approv switzerland canada australia sma
xlrp initi pivot phase trial xlrp
present initi proof concept data clear cell renal cell carcinoma
present stage data gangliosidosi
complet adult low mid-dos cohort
file ind sickl cell diseas
report result phase studi less ici respons tumor
report result phase ii nivolumab combin studi multipl solid tumor
report result monotherapi studi liver kidney transplant recipi cscc
initi pivot phase trial retin pigmentosa
report data nci trial combin checkpoint inhibitor gi cancer
initi piii studi hypertriglyceridemia
initi piii studi dyslipidemia
report addit data phase i/ii trial hemoglobinopathi
report initi data phase i/ii trial b-cell malign
submit ind file hemophilia
vy-aadc present result trial result trial pd
figur regenxbio replimun uniqur expect import data read-out
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ benitec biopharma
biomarin lysogen oxford biomedica neutral vbl buy
figur week end genet medicin vivo gt ex vivo gt ge srna mrna
page
week-over-week perform chardan genet medicin vivo gene therapi ex vivo gene therapi gene edit srna mrna basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap gene therapyvectortickerratingccm ptupsideclosechang changemc mm solid genet n-f gene therapi exclud i/o vectortickerratingccm ptupsideclosechang changemc mm bluebird editingtechnologytickerratingccm ptupsideclosechang changemc mm allogen therapytechnologytickerratingccm ptupsideclosechang changemc mm translat pharmaceut
corpor report factset chardan note avx bold nite static market cap contribut post acquisit includ reflect valu creation within sector
figur public genet medicin vivo gt ex vivo gt gene edit srna mrna therapi companiesend-monthli market cap select compani januari present
page
cap million chardan genet medicin ivgt evgt ge srna/mrna monthli sector pharmaceut
corpor report factset chardan note avx bold nite static market cap contribut post acquisit includ reflect valu creation within sector ise
ly pa oxb ln exclud due either modest size and/or histor non-vector-gt and/or ex vivo gt exposur confound analys vivo gt sector valuat
figur public vivo gene therapi companiesend-monthli market cap select compani januari present
page
cap million vivogen therapi monthli sector valuationabeoadvmagtcavxsboldfixxkrysmgtxniteonceprvlqurergnxsight-parsldbvygr pharmaceut
figur public ex vivo gene therapi companiesend-monthli market cap select compani januari present
page
cap million ex vivogen therapi monthli sector valuationavrobluembioortxrubi pharmaceut
figur public gene edit companiesend-monthli market cap select compani januari present
page
cap million gene edit monthli sector valuat pharmaceut
corpor report factset chardan atrx bntc rgl sln ln exclud due modest size
figur public srna mrna therapi companiesend-monthli market cap select compani januari present
page
cap million srna mrna therapi monthli sector valuationabusalnyarctarwrbntxdrnamrnatbio pharmaceut
vivo gene therapi comp krystal meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name ise model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public vivo gene therapi companiesw prefer buy buy buy qure buy greater potenti drive upsid space
page
targettargetccmpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog medicinesfixxbuyaav n-f pharmaceuticalsrcktbuyaav privat vivogt compani molecular akouo ask cardiac inhibitor estev freelin gener horama stride tamid taysha gene therapi tenaya vivet note marin lysogen ultragenyx addit unrat public compani genethon relev non-profit organ pharmaceut
gene edit comp see greater upsid potenti intellia
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name cll model current market cap
figur gene editingw broadli expect out-performance crispr gene edit sector higher potenti perform buy
page
targettargetccmpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof privat gene edit companiescarib scienc egenesi emendo therapeut excis mammoth scienc myogen poseida recombinet spotlight trucod gene repair verv technolog pharmaceut
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name bntx model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
price prv
figur prioriti review voucher prv sold million million
page
date fda rpdd
ultragenyx genetx
retin pigmentosa exon mutat
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
